Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Keryx Biopharmaceuticals Ramps up Spending, Posts Second Quarter Loss

By Pharmaceutical Processing | August 9, 2010

NEW YORK (AP) — Keryx Biopharmaceuticals reported a second-quarter loss as it ramped up spending on drug candidates.

Keryx has no products on the market. It posted a profit a year ago due to $18.3 million in revenue from two of its partners.

On Sunday, Keryx said it lost $5.2 million, or 9 cents per share. It had no revenue in the three months ended June 30. A year earlier the company posted a profit of $14.1 million, or 29 cents per share. Keryx recorded $18.4 million in revenue then, most of it deferred revenue from Japan Tobacco Inc. and Torii Pharmaceutical Co., which had licensed Keryx’s drug Zerenex in Japan.

The results this year were in line with analyst expectations.

In the most recent quarter, Keryx said its research and development costs doubled to $3.6 million.

Keryx is running late stage clinical trials of Zerenex as a treatment for high phosphate levels, and perifosine as a treatment for multiple myeloma and colorectal cancer. It is developing perifosine through a partnership with and AEterna Zentaris Inc. and is also testing the drug against other cancers.

Keryx Biopharmaceuticals Inc. licensed Zerenex to Japan Tobacco and Torii Pharmaceutical in 2007. The company later amended the license agreement to eliminate most of its obligations.

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE